Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 302 publications
Anti-PD-(L)1 plus chemotherapy in advanced PD-L1-negative nonsquamous non-small cell lung cancer: a systematic review and meta-analysis.
Journal: Immunotherapy
Published: July 03, 2026
Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung Cancer.
Journal: The New England journal of medicine
Published: June 01, 2026
Brief Report: First-line Chemoimmunotherapy and Chemotherapy Outcomes in Patients with RET Fusion-Positive Lung Cancer in LIBRETTO-431.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: May 14, 2026
NTRK Gene Fusions: A Compendium of Fusion Partners and Tumor Types.
Journal: JCO precision oncology
Published: May 06, 2026
Metastatic Trajectories in Non-Small Cell Lung Cancer Guide Local and Systemic Therapies.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 05, 2026
A Phase 2 Basket Trial of Ado-Trastuzumab Emtansine for Patients with HER2 Amplified Cancers: A Non-Randomized Clinical Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 24, 2026
Cancer type-specific variation in patterns of driver alterations across 50,000 tumors.
Journal: Cancer cell
Published: April 19, 2026
The pan-tumor landscape, allelic status, and genomic complexity of SMARCA4 alterations.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 30, 2026
Clinicogenomic Characteristics and Treatment Outcomes of Patients With Advanced ALK-Rearranged Squamous and Adenosquamous Non-Small Cell Lung Cancers.
Journal: JCO precision oncology
Published: March 30, 2026
Clinical Outcomes for Patients who Received Both Trastuzumab Deruxtecan (T-DXd) and Trastuzumab Emtansine (T-DM1) for HER2-Mutant non-Small Cell Lung Cancer.
Journal: JTO clinical and research reports
Published: January 21, 2026
Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib: Results from the RET-MAP Registry.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 23, 2025
Last Updated: 09/26/2026